Cardinal Health stock gains on fresh earnings growth guidance

Published on 09/14/2026 at 22:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cardinal Health stock is supported by new guidance for fiscal 2027 EPS growth of 13% to 15% announced on September 14, 2026. The company also plans USD 1 billion in share repurchases, underlining confidence in cash flow.

Fotorealistisches Pharma-Distributionslager mit Gabelstapler und Mitarbeitern in Dublin Ohio — Cardinal Health Inc. betreibt ein modernes Pharma-Distributionslager in Dublin, Ohio – ISIN US14149Y1082, Illustration mit AI erstellt.

Cardinal Health stock (ISIN US14149Y1082) is drawing investor attention after the company outlined fresh guidance for fiscal 2027 earnings per share growth of 13% to 15% on September 14, 2026, at the Morgan Stanley 24th Annual Global Healthcare Conference. According to Investing.com, this guidance sits above the company’s long-term EPS growth target of 12% to 14%, signaling management’s confidence in the earnings outlook.

Guidance points to above-target EPS growth

As Investing.com reports, Cardinal Health guided fiscal 2027 EPS growth of 13% to 15%, compared with its stated long-term EPS growth target of 12% to 14%, giving investors a quantified signal that near-term performance is expected to outpace the strategic trajectory. Management described fiscal 2026 as a 'five for five' year, with all five operating segments delivering strong profit and cash flow, providing a base from which the higher growth guidance is set.

The conference transcript indicates that specialty and pharmaceutical investments are key drivers behind the outlook, with specialty-related revenue growth highlighted as a standout contributor in fiscal 2026, where specialty growth reached about 25% for the year. According to a transcript overview on TradingView, the company reiterated that its long-term EPS growth target remains at 12% to 14%, making the 13% to 15% range for fiscal 2027 a modest but meaningful step above the strategic baseline.

Cash returns and segment performance underpin the outlook

In addition to earnings guidance, Cardinal Health plans USD 1 billion in share repurchases in fiscal 2027, supported by what management described as continued strong cash flow. As Investing.com Brasil summarizes, the company believes its balance sheet and cash generation give it room both to invest in growth areas and to return capital to shareholders through buybacks.

Management emphasized that fiscal 2026 saw all five operating segments delivering strong profit and cash flow, characterizing the year as a 'five for five' outcome. This broad-based performance is important context for investors assessing the new guidance: EPS growth of 13% to 15% in fiscal 2027 is building on a year where segment results were already robust, rather than trying to recover from weakness. With specialty revenue growth around 25% in fiscal 2026, growth in that area stands well above typical mid-single-digit rates seen in more mature distribution segments, underscoring where Cardinal Health currently sees the strongest incremental opportunities.

Stock level and investor perspective

Per recent data accompanying the Morgan Stanley conference coverage on September 14, 2026, Cardinal Health shares were shown with a modest daily gain of about 0.23%, indicating a measured positive reaction rather than a sharp move. The price context suggests that investors view the 13% to 15% fiscal 2027 EPS growth guidance as supportive but not radically altering the risk profile, especially given that it only modestly exceeds the long-term 12% to 14% EPS growth target already communicated by the company.